Literature DB >> 22888393

A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma.

Driffa Moussata, Abdellah Bessayah, Marion Chauvenet, Karine Stroeymeyt, Giles Boschetti, Eddy Cotte, Olivier Glehen, S Issac, Françoise Mornex, Gilles Freyer, C Lombard-Bohas, Jean Christophe Saurin, Bernard Flourie.   

Abstract

Entities:  

Year:  2012        PMID： 22888393      PMCID： PMC3415723     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  9 in total

1.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

2.  Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma.

Authors:  K M McMasters; T M Tuttle; S D Leach; T Rich; K R Cleary; D B Evans; S A Curley
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Authors:  C Louvet; R Labianca; P Hammel; G Lledo; M G Zampino; T André; A Zaniboni; M Ducreux; E Aitini; J Taïeb; R Faroux; C Lepere; A de Gramont
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

5.  Recurrent cholangiocarcinoma: negative autopsy results after aggressive management.

Authors:  H Ashamalla; G Kostandy; S Salama; M Ghaly; H Taha; E Toni; B Sosler; P Chandra
Journal:  South Med J       Date:  2000-06       Impact factor: 0.954

6.  Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

Authors:  Atul Sharma; Amit Dutt Dwary; Bidhu Kalyan Mohanti; Surya V Deo; Sujoy Pal; Vishnu Sreenivas; Vinod Raina; Nootan Kumar Shukla; Sanjay Thulkar; Pramod Garg; Surendra Pal Chaudhary
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

Review 7.  Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2.

Authors:  William P Daines; Vandana Rajagopalan; Michael L Grossbard; Peter Kozuch
Journal:  Oncology (Williston Park)       Date:  2004-07       Impact factor: 2.990

8.  Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

Authors:  T André; C Tournigand; O Rosmorduc; S Provent; F Maindrault-Goebel; D Avenin; F Selle; F Paye; L Hannoun; S Houry; B Gayet; J P Lotz; A de Gramont; C Louvet
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

Review 9.  Emerging drugs for biliary cancer.

Authors:  Florian Eckel; Roland M Schmid
Journal:  Expert Opin Emerg Drugs       Date:  2007-11       Impact factor: 4.191
  9 in total
  2 in total

1.  A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report.

Authors:  Takeshi Watanabe; Junji Furuse; Naohiro Okano; Yutaka Suzuki; Hiroshi Kamma; Masanori Sugiyama
Journal:  Surg Case Rep       Date:  2017-02-12

2.  Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report.

Authors:  Yuya Miura; Ryo Ashida; Teiichi Sugiura; Katsuhisa Ohgi; Mihoko Yamada; Shimpei Otsuka; Akiko Todaka; Katsuhiko Uesaka
Journal:  Surg Case Rep       Date:  2022-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.